Clinical trial NCT00041808: Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
Official title: A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (Via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the Liver .
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Metastases, Neoplasm
Colorectal Neoplasms
Esophageal Neoplasms
Stomach Neoplasms
Pancreatic Neoplasms
Breast Neoplasms
Melanoma
Sarcoma
Gastrointestinal Neoplasms
Lung Neoplasms
Liver Neoplasms
Cholangiocarcinoma
Keywords: Metastatic liver cancer
Cholangiocarcinoma
colorectal cancer
esophageal cancer
gastric cancer
pancreatic cancer
breast cancer
malignant melanoma
sarcoma
GIST
gastrointestinal stromal tumor
lung cancer
liver cancer
Lead sponsor: FeRx
Sponsor class: INDUSTRY
First posted: 2002-07-19
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon. When DOX is added to MTCs, DOX attaches to the carbon part of the MTCs. MTC-DOX is directed to and deposited in the area of a tumor, where it is thought that it then "leaks" through the blood vessel walls. Once in the surrounding tissues, it is thought that Doxorubicin becomes "free from" the magnetic beads and will then be able to act against the tumor cells. The iron component of the particle has magnetic properties, making it possible to direct MTC-DOX to specific tumor sites in the liver by placing a magnet on the body surface. It is hoped that MTC-DOX used with the magnet may target the chemotherapy drug directly to liver tumors and provide a treatment to patients with cancers that have spread to the liver.


Eligibility criteria: Inclusion Criteria

* Patients with a Karnofsky (or equivalent) performance status \> 60 and an expected survival of \> 2 months
* Patients agreeing to use a medically effective method of contraception
* Patients able to understand and give written informed consent
* The center of the tumor mass must be \< or = 14 cm from the anterior or lateral abdominal wall as determined by cross sectional imaging measured at baseline. This is required for optimal retention of MTC-DOX by the magnetic field. If more than one tumor mass is present, all of the treated tumor masses must meet this criterion

Exclusion Criteria

* Women who are pregnant or lactating
* Patient's with metastatic liver cancer, or other primary liver cancer excluding HCC, with diffuse disease that does not have focal area(s) conducive to local regional therapy
* Patients with the following laboratory abnormalities:Hemoglobin \< 10.0 g/dL;Granulocyte count \< 1,500 per mm3;Platelet count \< 50,000 per mm3; Lymphocyte count \< 0.5 x 10 to the 9th per L; Total bilirubin \>/= 3.0 mg/dL;AST or ALT \>/= 5x the upper limit of normal;INR \>/= 1.3; Creatinine \>/= 2.0 mg/dL
* Patients with either significant cardiovascular disease or any other organ system dysfunction which, in the opinion of the investigator, would either compromise the patient's safety or interfere with the evaluation of the test material. Patients with evidence of a myocardial infarction within six (6) months prior to this trial will be excluded.
* Patients with an indwelling cardiac pacemaker, cerebral aneurysm clips, or any other indwelling device or appliance that could be adversely affected by the use of the external magnet
* Patients at the time of study entry with a second invasive cancer other than basal cell and squamous cell carcinoma of the skin, or carcinoma in situ of the cervix
* Patients with documented evidence of hemachromatosis or hemosiderosis
* Patients with CT or ultrasound evidence of portal vein invasion or thrombosis
* Patients who have had prior anthracycline therapy with a left ventricular ejection fraction (LVEF) \<50%, as measured by either multigated radionuclide angiography (MUGA) scan or echocardiogram.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Scripps Stevens Cancer Division
state: California
city: San Francisco
country: United States
facility: UCSF Cancer Center
state: California
city: Temple
country: United States
facility: Scott and White Clinic
state: Texas
city: Frankfurt
country: Germany
facility: Frankfurt Universtiy
Study officials:
name: Joy Koda, PhD
role: STUDY_CHAIR
References: